1
|
Xin J, Pu Q, Wang R, Gu Y, He L, Du X, Tang G, Han D. Antibacterial activity and mechanism of chelerythrine against Streptococcus agalactiae. Front Vet Sci 2024; 11:1408376. [PMID: 38948675 PMCID: PMC11212505 DOI: 10.3389/fvets.2024.1408376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Accepted: 05/20/2024] [Indexed: 07/02/2024] Open
Abstract
Streptococcus agalactiae (S.agalactiae), also known as group B Streptococcus (GBS), is a highly infectious pathogen. Prolonged antibiotic usage leads to significant issues of antibiotic residue and resistance. Chelerythrine (CHE) is a naturally occurring benzophenidine alkaloid and chelerythrine chloride (CHEC) is its hydrochloride form with diverse biological and pharmacological activities. However, the antibacterial mechanism of CHEC against GBS remains unclear. Thus, this study aims to investigate the in vitro antibacterial activity of CHEC on GBS and elucidate its underlying mechanism. The antibacterial effect of CHEC on GBS was assessed using inhibitory zone, minimum inhibitory concentration (MIC), and minimum bactericidal concentration (MBC) assays, as well as by constructing a time-kill curve. The antibacterial mechanism of CHEC was investigated through techniques such as scanning electron microscopy (SEM) and transmission electron microscopy (TEM), measurement of alkaline phosphatase (AKP) activity, determination of Na+ K+, Ca2+ Mg2+-adenosine triphosphate (ATP) activity, observation of membrane permeability, and analysis of intracellular reactive oxygen species (ROS) and mRNA expression levels of key virulence genes. The results demonstrated that the inhibition zone diameters of CHEC against GBS were 14.32 mm, 12.67 mm, and 10.76 mm at concentrations of 2 mg/mL, 1 mg/mL, and 0.5 mg/mL, respectively. The MIC and MBC values were determined as 256 μg/mL and 512 μg/mL correspondingly. In the time-kill curve, 8 × MIC, 4 × MIC and 2 × MIC CHEC could completely kill GBS within 24 h. SEM and TEM analyses revealed significant morphological alterations in GBS cells treated with CHEC including shrinkage, collapse, and leakage of cellular fluids. Furthermore, the antibacterial mechanism underlying CHEC's efficacy against GBS was attributed to its disruption of cell wall integrity as well as membrane permeability resulting in extracellular release of intracellular ATP, AKP, Na+ K+, Ca2+ Mg2+. Additionally CHEC could increase the ROS production leading to oxidative damage and downregulating mRNA expression levels of key virulence genes in GBS cells. In conclusion, CHEC holds potential as an antimicrobial agent against GBS and further investigations are necessary to elucidate additional molecular mechanisms.
Collapse
Affiliation(s)
- Jige Xin
- College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
| | - Qiqi Pu
- College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
| | - Ruiying Wang
- College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
| | - Yeqing Gu
- College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
| | - Lin He
- College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
| | - Xuan Du
- College of Veterinary Medicine, Yunnan Agricultural University, Kunming, China
| | - Guowen Tang
- College of Plant Protection, Yunnan Agricultural University, Kunming, China
| | - Diangang Han
- Technology Center of Kunming Customs, Kunming, China
| |
Collapse
|
2
|
Nwokebu GC, Adesina AB, Isibor CN, Aigbepue SA, Egbo CC, Pureaziba N, Isaac OO, Owolade AJJ, Alabere HO, Iwuagwu MO, Hussein MO, Ibrahim A, Balogun TA. Identification of Phytochemicals with Inhibitory Potential Against Beta-lactamase Enzymes via Computer-aided Approach. Bioorg Chem 2024; 145:107238. [PMID: 38412652 DOI: 10.1016/j.bioorg.2024.107238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2023] [Revised: 02/19/2024] [Accepted: 02/20/2024] [Indexed: 02/29/2024]
Abstract
INTRODUCTION Antibacterial drugs have been widely used for the past century to treat diseases, but their efficacy has been limited by multi-resistant pathogens, particularly those that utilize beta-lactamase enzymes. The inhibition of beta-lactamase enzymes holds great promise for reducing the influence of such pathogens. OBJECTIVE This study aims to evaluate the mechanism of inhibition of phytochemicals with antibacterial activity against two classes of beta-lactamases using computational methods. METHODS To achieve this objective, a total of thirty phytochemicals were docked against SHV-1 beta-lactamase and AmpC beta-lactamase after procurement from Protein Data Bank. The pharmacokinetics (ADMET) and density functional theory (DFT) analysis study were also conducted to unravel the nature of the top six most promising compounds on each protein. RESULTS The results showed that a significant percentage of the compounds had binding affinities greater than that of avibactam, the positive control. Quercetin-3-O-rutinoside showed the most promising results against SHV-1 beta-lactamase with an affinity of -9.4 kcal/mol, while luteolin was found to be the most promising candidate against AmpC beta-lactamase with an affinity of -8.5 kcal/mol. DFT analysis demonstrated the reactivity of these compounds, and the ADMET study indicated that they were relatively safe. CONCLUSION In conclusion, the study's findings suggest that the selected compounds have significant potential to inhibit beta-lactamase and may be used in combination with antibiotics against organisms that produce beta-lactamase. This study provides a basis for further research in a wet-lab setting to validate the results.
Collapse
Affiliation(s)
- Goodness Chizorom Nwokebu
- Department of Pharmaceutical and Medicinal Chemistry, University of Nigeria, Nsukka, Enugu State, Nigeria; Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria
| | - Abdurahman Babatunde Adesina
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Veterinary Public Health and Preventive Medicine, Usmanu Danfodiyo University, Sokoto, Nigeria
| | - Clement Ndudi Isibor
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Biological Sciences, University of Delta, Agbor, Delta State, Nigeria
| | - Stephen Ayaosi Aigbepue
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Pharmacology and Therapeutics, University of Ibadan, Nigeria
| | - Chidinma Confidence Egbo
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Pharmaceutical and Medicinal Chemistry, University of Nigeria, Nsukka, Nigeria
| | - Nelson Pureaziba
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Microbiology, Niger Delta University, Delta State, Nigeria
| | - Opeyemi Oluwafemi Isaac
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Chemistry, Adekunle Ajasin University, Akungba-Akoko, Ondo State, Nigeria
| | - Adedoyin John-Joy Owolade
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Faculty of Pharmacy, Obafemi Awolowo University, Ile Ife, Osun State, Nigeria
| | - Hafsat Olateju Alabere
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Life Sciences, Aberystwyth University, United Kingdom
| | - Mary Oluchi Iwuagwu
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Plant Science and Biotechnology, Abia State University, Uturu, Abia State, Nigeria
| | - Mutiat Olamide Hussein
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Biology Unit, Department of Biological Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria
| | - Abdulwasiu Ibrahim
- Institute of Bioinformatics and Molecular Therapeutics, Oshogbo, Osun State, Nigeria; Department of Biochemistry and Molecular Biology, Usmanu Danfodiyo University, Sokoto, Nigeria; Kwara Emerging Scholars Forum, Ilorin, Kwara State, Nigeria.
| | | |
Collapse
|
3
|
Zhai X, Wu G, Tao X, Yang S, Lv L, Zhu Y, Dong D, Xiang H. Success stories of natural product-derived compounds from plants as multidrug resistance modulators in microorganisms. RSC Adv 2023; 13:7798-7817. [PMID: 36909750 PMCID: PMC9994607 DOI: 10.1039/d3ra00184a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2023] [Accepted: 03/01/2023] [Indexed: 03/14/2023] Open
Abstract
Microorganisms evolve resistance to antibiotics as a function of evolution. Antibiotics have accelerated bacterial resistance through mutations and acquired resistance through a combination of factors. In some cases, multiple antibiotic-resistant determinants are encoded in these genes, immediately making the recipient organism a "superbug". Current antimicrobials are no longer effective against infections caused by pathogens that have developed antimicrobial resistance (AMR), and the problem has become a crisis. Microorganisms that acquire resistance to chemotherapy (multidrug resistance) are a major obstacle for successful treatments. Pharmaceutical industries should be highly interested in natural product-derived compounds, as they offer new sources of chemical entities for the development of new drugs. Phytochemical research and recent experimental advances are discussed in this review in relation to the antimicrobial efficacy of selected natural product-derived compounds as well as details of synergistic mechanisms and structures. The present review recognizesand amplifies the importance of compounds with natural origins, which can be used to create safer and more effective antimicrobial drugs by combating microorganisms that are resistant to multiple types of drugs.
Collapse
Affiliation(s)
- Xiaohan Zhai
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Guoyu Wu
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Xufeng Tao
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Shilei Yang
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Linlin Lv
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Yanna Zhu
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Deshi Dong
- Department of Pharmacy, First Affiliated Hospital of Dalian Medical University Dalian China
| | - Hong Xiang
- Laboratory of Integrative Medicine, First Affiliated Hospital of Dalian Medical University Dalian China
| |
Collapse
|
4
|
Suganya T, Packiavathy IASV, Aseervatham GSB, Carmona A, Rashmi V, Mariappan S, Devi NR, Ananth DA. Tackling Multiple-Drug-Resistant Bacteria With Conventional and Complex Phytochemicals. Front Cell Infect Microbiol 2022; 12:883839. [PMID: 35846771 PMCID: PMC9280687 DOI: 10.3389/fcimb.2022.883839] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2022] [Accepted: 05/02/2022] [Indexed: 12/22/2022] Open
Abstract
Emerging antibiotic resistance in bacteria endorses the failure of existing drugs with chronic illness, complicated treatment, and ever-increasing expenditures. Bacteria acquire the nature to adapt to starving conditions, abiotic stress, antibiotics, and our immune defense mechanism due to its swift evolution. The intense and inappropriate use of antibiotics has led to the development of multidrug-resistant (MDR) strains of bacteria. Phytochemicals can be used as an alternative for complementing antibiotics due to their variation in metabolic, genetic, and physiological fronts as well as the rapid evolution of resistant microbes and lack of tactile management. Several phytochemicals from diverse groups, including alkaloids, phenols, coumarins, and terpenes, have effectively proved their inhibitory potential against MDR pathogens through their counter-action towards bacterial membrane proteins, efflux pumps, biofilms, and bacterial cell-to-cell communications, which are important factors in promoting the emergence of drug resistance. Plant extracts consist of a complex assortment of phytochemical elements, against which the development of bacterial resistance is quite deliberate. This review emphasizes the antibiotic resistance mechanisms of bacteria, the reversal mechanism of antibiotic resistance by phytochemicals, the bioactive potential of phytochemicals against MDR, and the scientific evidence on molecular, biochemical, and clinical aspects to treat bacterial pathogenesis in humans. Moreover, clinical efficacy, trial, safety, toxicity, and affordability investigations, current status and developments, related demands, and future prospects are also highlighted.
Collapse
Affiliation(s)
- Thangaiyan Suganya
- Department of Microbiology, Karpagam Academy of Higher Education, Coimbatore, India
| | | | - G. Smilin Bell Aseervatham
- Post Graduate Research Department of Biotechnology and Bioinformatics, Holy Cross College (Autonomous), Tiruchirappalli, India
| | - Areanna Carmona
- Francis Graduate School of Biomedical Sciences, Texas Tech University Health Science Center of El Paso, Texas, TX, United States
| | - Vijayaragavan Rashmi
- National Repository for Microalgae and Cyanobacteria (NRMC)- Marine, National Facility for Marine Cyanobacteria, (Sponsored by Department of Biotechnology (DBT), Government of India), Bharathidasan University, Tiruchirappalli, India
| | | | | | - Devanesan Arul Ananth
- Department of Biotechnology, Karpagam Academy of Higher Education, Coimbatore, India
| |
Collapse
|
5
|
Ma H, Lai B, Zan C, Di X, Zhu X, Wang K. GLO1 Contributes to the Drug Resistance of Escherichia coli Through Inducing PER Type of Extended-Spectrum β-Lactamases. Infect Drug Resist 2022; 15:1573-1586. [PMID: 35414749 PMCID: PMC8995003 DOI: 10.2147/idr.s358578] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2022] [Accepted: 03/26/2022] [Indexed: 12/16/2022] Open
Abstract
Background Escherichia coli-associated antimicrobial resistance (AMR) issue so far needs urgent considerations. This study aims to screen the potent genes associated with extended-spectrum β-lactamases (ESBLs) in drug-resistant Escherichia coli and elucidate the specific drug-resistant mechanism. Methods Clinical ESBLs-EC samples were obtained based on the microbial identification, and the whole genome was sequenced. In combination with the significantly enriched pathways, several differently expressed genes were screened and verified by RT-PCR. Furthermore, through knocking out glyoxalase 1 (GLO1) gene and transfecting overexpressed plasmids, the potential relationship between GLO1 and ESBLs was then investigated. Lastly, the concentrations of β-lactamases in bacteria and supernatant from different groups were examined by enzyme-linked immunosorbent assay (ELISA). Results After successful isolation and identification of ESBLs-EC, the whole genome and eighteen differential metabolic pathways were analyzed to select differently expressed genes, including add, deoD, guaD, speG, GLO1, VNN1, etc. RT-PCR results showed that there were no differences in these genes between the standard bacteria and susceptible Escherichia coli. Remarkably, the relative levels of four genes including speG, Hdac10, GLO1 and Ppcdc were significantly increased in ESBLs-EC in comparison with susceptible strains, whereas other gene expression was decreased. Further experiments utilizing gene knockout and overexpression strains confirmed the role of GLO1. At last, a total of 10 subtypes of β-lactamases were studied using ELISA, including BES-, CTX-M1-, CTX-M2-, OXA1-, OXA2-, OXA10-, PER-, SHV-, TEM-, and VEB-ESBLs, and results demonstrated that GLO1 gene expression only affected PER-β-lactamases but had no effects on other β-lactamases. Conclusion SpeG, Hdac10, GLO1 and Ppcdc might be associated with the drug-resistant mechanism of Escherichia coli. Of note, this study firstly addressed the role of GLO1 in the drug resistance of ESBLs-EC, and this effect may be mediated by increasing PER-β-lactamases.
Collapse
Affiliation(s)
- He Ma
- Department of Anesthesiology, The Second Hospital of Jilin University, Changchun, 130042, People’s Republic of China
| | - Bingjie Lai
- Department of Intensive Care Unit, The Second Hospital of Jilin University, Changchun, 130042, People’s Republic of China
| | - Chunfang Zan
- Division of Vascular Biology, Institute for Stroke and Dementia Research (ISD), LMU Klinikum, Ludwig-Maximilians-University (LMU), Munich, 81377, Germany
| | - Xin Di
- Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, 130042, People’s Republic of China
| | - Xinran Zhu
- Department of Anesthesiology, The Second Hospital of Jilin University, Changchun, 130042, People’s Republic of China
| | - Ke Wang
- Department of Respiratory Medicine, The Second Hospital of Jilin University, Changchun, 130042, People’s Republic of China
| |
Collapse
|
6
|
Khameneh B, Eskin NAM, Iranshahy M, Fazly Bazzaz BS. Phytochemicals: A Promising Weapon in the Arsenal against Antibiotic-Resistant Bacteria. Antibiotics (Basel) 2021; 10:1044. [PMID: 34572626 PMCID: PMC8472480 DOI: 10.3390/antibiotics10091044] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 08/16/2021] [Accepted: 08/17/2021] [Indexed: 12/12/2022] Open
Abstract
The extensive usage of antibiotics and the rapid emergence of antimicrobial-resistant microbes (AMR) are becoming important global public health issues. Many solutions to these problems have been proposed, including developing alternative compounds with antimicrobial activities, managing existing antimicrobials, and rapidly detecting AMR pathogens. Among all of them, employing alternative compounds such as phytochemicals alone or in combination with other antibacterial agents appears to be both an effective and safe strategy for battling against these pathogens. The present review summarizes the scientific evidence on the biochemical, pharmacological, and clinical aspects of phytochemicals used to treat microbial pathogenesis. A wide range of commercial products are currently available on the market. Their well-documented clinical efficacy suggests that phytomedicines are valuable sources of new types of antimicrobial agents for future use. Innovative approaches and methodologies for identifying plant-derived products effective against AMR are also proposed in this review.
Collapse
Affiliation(s)
- Bahman Khameneh
- Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran;
| | - N. A. Michael Eskin
- Department of Food and Human Nutritional Sciences, Faculty of Agricultural and Food Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada;
| | - Milad Iranshahy
- Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran
| | - Bibi Sedigheh Fazly Bazzaz
- Department of Pharmaceutical Control, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran;
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948954, Iran
| |
Collapse
|
7
|
Antunes JC, Domingues JM, Miranda CS, Silva AFG, Homem NC, Amorim MTP, Felgueiras HP. Bioactivity of Chitosan-Based Particles Loaded with Plant-Derived Extracts for Biomedical Applications: Emphasis on Antimicrobial Fiber-Based Systems. Mar Drugs 2021; 19:md19070359. [PMID: 34201803 PMCID: PMC8303307 DOI: 10.3390/md19070359] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Revised: 06/14/2021] [Accepted: 06/21/2021] [Indexed: 01/16/2023] Open
Abstract
Marine-derived chitosan (CS) is a cationic polysaccharide widely studied for its bioactivity, which is mostly attached to its primary amine groups. CS is able to neutralize reactive oxygen species (ROS) from the microenvironments in which it is integrated, consequently reducing cell-induced oxidative stress. It also acts as a bacterial peripheral layer hindering nutrient intake and interacting with negatively charged outer cellular components, which lead to an increase in the cell permeability or to its lysis. Its biocompatibility, biodegradability, ease of processability (particularly in mild conditions), and chemical versatility has fueled CS study as a valuable matrix component of bioactive small-scaled organic drug-delivery systems, with current research also showcasing CS’s potential within tridimensional sponges, hydrogels and sutures, blended films, nanofiber sheets and fabric coatings. On the other hand, renewable plant-derived extracts are here emphasized, given their potential as eco-friendly radical scavengers, microbicidal agents, or alternatives to antibiotics, considering that most of the latter have induced bacterial resistance because of excessive and/or inappropriate use. Loading them into small-scaled particles potentiates a strong and sustained bioactivity, and a controlled release, using lower doses of bioactive compounds. A pH-triggered release, dependent on CS’s protonation/deprotonation of its amine groups, has been the most explored stimulus for that control. However, the use of CS derivatives, crosslinking agents, and/or additional stabilization processes is enabling slower release rates, following extract diffusion from the particle matrix, which can find major applicability in fiber-based systems within ROS-enriched microenvironments and/or spiked with microbes. Research on this is still in its infancy. Yet, the few published studies have already revealed that the composition, along with an adequate drug release rate, has an important role in controlling an existing infection, forming new tissue, and successfully closing a wound. A bioactive finishing of textiles has also been promoting high particle infiltration, superior washing durability, and biological response.
Collapse
|
8
|
Zhao NJ, Wang LL, Liu ZY, Wang Q, Liu L, Sun ZL, Wu Y. Pharmacokinetics of Chelerythrine and Its Metabolite after Oral and Intramuscular Administrations in Pigs. Xenobiotica 2021; 51:1264-1270. [PMID: 33538636 DOI: 10.1080/00498254.2021.1882714] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The objective of this study was to investigate the single- and multiple-dose pharmacokinetics of chelerythrine (CHE) and its metabolite, dihydrochelerythrine (DHCHE), after oral and IM administrations in pigs.Six crossbreed (Landrace × Large White) female pigs (7 to 8 weeks old; 24.1 ± 2.6 kg bw) administered oral and IM CHE at a dose of 0.1 mg/kg orally and intramuscularly in a cross-over design. Multiple oral administration was performed at 0.1 mg/kg a time, three times a day at 8-h intervals for three consecutive days. Blood samples were collected from the anterior vena cava and placed into heparinized centrifuge tubes before dosing (time 0 h) and at different times after oral oral and IM administrations. Pretreatment plasma was analyzed by high-performance liquid chromatography tandem mass spectrometry.After IM administration, CHE and DHCHE rapidly reached peak concentrations (Cmax, 69.79 ± 15.41 and 3.47 ± 1.23 ng/ml) at 0.42 ± 0.13 and 0.33 ± 0.13 h, respectively. After single oral administration, CHE and DHCHE rapidly increased to reach Cmax of 5.04 ± 1.00 and 1.21 ± 0.35 ng/ml at 1.83 ± 0.26 and 1.67 ± 0.26 h, respectively. The half-life (T1/2) was 2.03 ± 0.26 and 2.56 ± 1.00 h for CHE and DHCHE, respectively. After multiple oral administration, the average steady-state concentrations (Css) of CHE and DHCHE were 2.51 ± 0.40 and 0.6 ± 0.06 ng/ml, respectively.CHE is metabolized rapidly after a single oral administration, multiple daily doses and long-term use of CHE are recommended.
Collapse
Affiliation(s)
- Na-Jiao Zhao
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| | - Li-Li Wang
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| | - Zhao-Ying Liu
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| | - Qin Wang
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| | - Lei Liu
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| | - Zhi-Liang Sun
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| | - Yong Wu
- Hunan Engineering Research Center of Veterinary Drug, College of Veterinary Medicine, Hunan Agricultural University, Changsha, Hunan 410128, China
| |
Collapse
|